# What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China?

Lymphoma

#CART #Lymphoma #DLBCL #LBCL #MedicalTourism #FL #MCL

In recent years, CAR-T cell therapy has sparked a revolution in cancer treatment worldwide, achieving remarkable results, especially in lymphoma care. As one of the global leaders in CAR-T therapy, China has attracted a large number of international patients seeking this cutting-edge immunotherapy. So, what types of lymphoma patients are suitable to travel to China for this advanced treatment?

## Indications: The First Choice for Relapsed or Refractory Lymphoma Patients

CAR-T treatment in China primarily targets patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Specific patient groups that are suitable include:

1. **Relapsed DLBCL**: Patients who did not respond to first-line treatments, such as R-CHOP, or relapsed within 12 months after treatment.

2. **Follicular Lymphoma (FL)**: Patients with grade 1-3a FL who have relapsed or are refractory after at least two lines of treatment.

3. **Mantle Cell Lymphoma (MCL)**: Patients whose disease remains difficult to control even after multiple treatments, including BTK inhibitors.

4. Patients whose lymphoma is resistant to traditional treatments or who experience rapid relapse after therapies such as conventional chemotherapy and targeted treatments.

5. More indications include diffuse large B-cell lymphoma (not otherwise specified), DLBCL transformed from follicular lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, as well as grade 3b follicular lymphoma.

CAR-T therapy offers new hope to these patients by targeting the CD19 antigen on the surface of tumor cells.

## Physical Condition: Stable Health is Key

While CAR-T therapy has shown significant efficacy, the potential for serious side effects, such as **cytokine release syndrome (CRS)** and **neurotoxicity**, means that patients must be in stable health to tolerate the risks associated with treatment. Suitable patients should meet the following conditions:

– **Good heart and lung function**: The patient’s cardiovascular and respiratory health should be adequate to handle the stress of treatment.

– **Normal liver and kidney function**: Liver enzymes (such as ALT) and creatinine levels should be within normal ranges to ensure that the patient can properly eliminate toxins from the body.

– **Stable immune system**: Patients should not have severe infections or immunosuppressed conditions, as CAR-T therapy can further weaken the immune system, increasing the risk of infection.

Additionally, patients need to achieve a performance status score of 0-1 on the ECOG scale, indicating that they have good functional ability and can handle daily activities independently.

## Pre-Treatment Testing: Ensuring Proper Antigen Expression

CAR-T therapy targets specific antigens (such as CD19) on the surface of tumor cells, so patients’ cancer cells must express these antigens for treatment to be effective. If tests show that the tumor cells do not express the relevant antigens, CAR-T therapy will not work effectively.

## Costs and Resources: The Advantages of CAR-T in China

Compared to Western countries, CAR-T therapy in China is relatively affordable, usually costing between hundreds of thousands to one million RMB, whereas in the U.S., CAR-T treatment can cost several hundred thousand dollars. For patients with the financial ability but who find it difficult to bear the high costs of treatment in the West, China offers a significant cost advantage.

Moreover, China boasts several top-tier hospitals with established CAR-T treatment programs, such as leading cancer centers in Beijing, Shanghai, and Guangzhou. These hospitals have extensive clinical experience, offering international patients convenient access to treatment.

## Contact Us:

The Advanced Medicine in China team has a wealth of connections with doctors and hospitals, enabling us to quickly help you find the most suitable hospital and expert team for your specific needs. In China, we provide a fast-track option for CAR-T treatment.

## Conclusion

With its cost advantages, advanced medical resources, and broad indications, CAR-T therapy in China has attracted a large number of international lymphoma patients. For those who have failed traditional treatments, are in good physical condition, and have sufficient financial means, CAR-T treatment in China is an ideal choice. If you or someone close to you meets these conditions, consider coming to China for world-leading CAR-T therapy, and open the door to new hope in the fight against cancer.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTherapy #CARTinChina #RelapsedLymphoma #RefractoryLymphoma #FollicularLymphoma #MantleCellLymphoma #Immunotherapy #CancerRevolution #AdvancedCancerCare #CD19Targeting #CancerHope #CancerCare #ChineseHospitals #GlobalHealth #CancerSurvivors #CARTSuccess #MedicalInnovation